During the third quarter, Gladstone Institutional Advisory LLC initiated a position in Madrigal Pharmaceuticals, acquiring 1,093 shares valued at approximately $501,000, according to its latest 13F filing with the SEC. This move follows significant adjustments by other major institutional investors: Adage Capital Partners increased its holdings by 96.3%, adding 184,554 shares to reach 376,163 shares; Norges Bank entered with a new stake valued near $53.4 million; Invesco Ltd. boosted its ownership by 50.7%, acquiring 67,422 additional shares for a total of 200,356; BNP Paribas Financial Markets expanded its position by 1,886.1%, ending the period with 69,037 shares; and Artisan Partners added 63,833 shares, a 46.3% increase to hold 201,571 shares. Institutional ownership now stands at 98.5% of outstanding stock.

In late 2023, insider selling accelerated, with Carole Huntsman disposing of 1,958 shares in November and CFO Mardi Dier selling 4,173 shares in early December, collectively reducing their combined stakes by over 16% and 28% respectively. Over the past three months, insiders have offloaded 77,056 shares valued at more than $41 million, representing 21.5% of total insider holdings. These transactions suggest profit-taking amid recent market volatility and ahead of key clinical and regulatory milestones.

Madrigal’s market capitalization stands at $11.67 billion, supported by a beta of –1.00 that underscores its low correlation with broader market swings. The company maintains strong liquidity, with a current ratio of 3.44 and a quick ratio of 3.26, while carrying a moderate debt-to-equity ratio of 0.54. Over the past 52 weeks, the stock has traded between its lows near $265 and highs close to $615, reflecting heightened investor interest as the Phase 3 candidate resmetirom advances toward potential regulatory filings.

Wall Street sentiment remains largely favorable: among 16 analysts covering Madrigal, one assigns a Strong Buy, 12 rate it Buy, two Hold, and one Sell, yielding an average recommendation of Moderate Buy. Price targets range from $266 to $900, with a mean target near $621. UBS and Oppenheimer have led the bullish calls, lifting objectives to $900 and $650 respectively, while Bank of America recently upgraded to Neutral and raised its target to $445. Consensus forecasts project negative EPS of approximately $23.47 for the current fiscal year, reflecting continued investment in the resmetirom program before potential commercial revenues materialize.